Pharmacokinetic and efficacy study of cisplatin and paclitaxel formulated in a new injectable poly(sebacic-co-ricinoleic acid) polymer

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 82, Issue 1, 2012, Pages 85-93

  Levy Nissenbaum, Etgar ^b   Khan, Wahid ^a   Pawar, Rajendra P ^c   Tabakman, Rinat ^b   Naftali, Esmira ^b   Winkler, Ilan ^b   Kaufman, Olga ^b   Klapper, Leah ^b   Domb, Abraham J ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b BIOLINERX LTD   (Israel)

^c DEOGIRI COLLEGE   (India)

Author keywords

Cisplatin; Efficacy study; Localized delivery system; Paclitaxel; Pharmacokinetics; Poly(sebacic co ricinoleic acid)

Indexed keywords

CISPLATIN; PACLITAXEL; POLY(SEBACIC CO RICINOLEIC ACID); POLYMER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BIOCOMPATIBILITY; BODY WEIGHT; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; HEAD AND NECK TUMOR; HUMAN; HUMAN CELL; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DECANOIC ACIDS; DELAYED-ACTION PREPARATIONS; HEAD AND NECK NEOPLASMS; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MICE; MICE, NUDE; PACLITAXEL; POLYMERS; RATS; RICINOLEIC ACIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84866010251     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2012.06.004     Document Type: Article

References (22)

1. M.B. Ferreira, J.P. Lima, and E.E. Cohen Novel targeted therapies in head and neck cancer Expert Opin. Investig. Drugs 21 2012 281 295
2. A.H. Shikani, and A.J. Domb Polymer chemotherapy for head and neck cancer Laryngoscope 110 2000 907 917
3. J. Kopecek Smart and genetically engineered biomaterials and drug delivery systems Eur. J. Pharm. Sci. 20 2003 1 16
4. R. Duncan The dawning era of polymer therapeutics Nat. Rev. Drug Discov. 2 2003 347 360
5. R.I. Pinhassi, Y.G. Assaraf, S. Farber, M. Stark, D. Ickowicz, S. Drori, A.J. Domb, and Y.D. Livney Arabinogalactan-folic acid-drug conjugate for targeted delivery and target-activated release of anticancer drugs to folate receptor-overexpressing cells Biomacromolecules 11 2010 294 303
6. E. Ruel-Gariepy, M. Shive, A. Bichara, M. Berrada, D. Le Garrec, A. Chenite, and J.C. Leroux A thermosensitive chitosan-based hydrogel for the local delivery of paclitaxel Eur. J. Pharm. Biopharm. 57 2004 53 63
7. J.Y. Joung, W.A. Kwon, I.C. Cho, E.K. Kim, S. Park, H. Yoon, H.K. Seo, J. Chung, W.S. Park, and K.H. Lee Paclitaxel and cisplatin chemotherapy for metastatic urothelial carcinoma after failure of two courses of platinum-based regimens Int. J. Urol. 18 2011 350 357
8. J.M. Terwogt, B. Nuijen, W.W. Huinink, and J.H. Beijnen Alternative formulations of paclitaxel Cancer Treat. Rev. 23 1997 87 95
9. K.J. Harrington, G. Rowlinson-Busza, K.N. Syrigos, R.G. Vile, P.S. Uster, A.M. Peters, and J.S. Stewart Pegylated liposome-encapsulated doxorubicin and cisplatin enhance the effect of radiotherapy in a tumor xenograft model Clin. Cancer Res. 6 2000 4939 4949
10. H. Li, C. Wang, Y. Wen, and H. Wu Treatment of squamous cell carcinoma of the tongue using arterial embolism with cisplatin-loaded albumin microspheres: a microstructural and ultrastructural investigation Chin. J. Dent. Res. 2 1999 61 66
11. T. Nishita Heat-sensitive liposomes containing cisplatin and localized hyperthermia in treatment of murine tumor Osaka City Med. J. 44 1998 73 83
12. A. Hatefi, and B. Amsden Biodegradable injectable in situ forming drug delivery systems J. Control Release 80 2002 9 28
13. S.K. Dordunoo, A.M.C. Oktaba, W. Hunter, W. Min, T. Cruz, and H.M. Burt Release of taxol from poly(epsilon-caprolactone) pastes: effect of water-soluble additives J. Control. Release 44 1997 87 94
14. J. Slager, B. Tyler, A. Shikanov, A.J. Domb, K. Shogen, D. Sidransky, and H. Brem Local controlled delivery of anti-neoplastic RNAse to the brain Pharm. Res. 26 2009 1838 1846
15. S. Shikanov, A. Shikanov, O. Gofrit, A. Nyska, B. Corn, and A.J. Domb Intratumoral delivery of paclitaxel for treatment of orthotopic prostate cancer J. Pharm. Sci. 98 2009 1005 1014
16. B. Amsden, A. Hatefi, D. Knight, and E. Bravo-Grimaldo Development of biodegradable injectable thermoplastic oligomers Biomacromolecules 5 2004 637 642
17. M.Y. Krasko, and A.J. Domb Hydrolytic degradation of ricinoleic-sebacic- ester-anhydride copolymers Biomacromolecules 6 2005 1877 1884
18. A. Shikanov, and A.J. Domb Poly(sebacic acid-co-ricinoleic acid) biodegradable injectable in situ gelling polymer Biomacromolecules 7 2006 288 296
19. M.Y. Krasko, A. Shikanov, A. Ezra, and A.J. Domb Poly(ester anhydride)s prepared by the insertion of ricinoleic acid into poly(sebacic acid) J. Polym. Sci. Pol. Chem. 41 2003 1059 1069
20. A. Shikanov, S. Shikanov, B. Vaisman, J. Golenser, and A.J. Domb Paclitaxel tumor biodistribution and efficacy after intratumoral injection of a biodegradable extended release implant Int. J. Pharm. 358 2008 114 120
21. M. Hakkarainen Aliphatic polyesters: abiotic and biotic degradation and degradation products Degradable Aliphatic Polyesters 2002 Springer Berlin/Heidelberg 113 138
22. B. Vaisman, M. Motiei, A. Nyska, and A.J. Domb Biocompatibility and safety evaluation of a ricinoleic acid-based poly(ester-anhydride) copolymer after implantation in rats J. Biomed Mater. Res. A 92 2010 419 431